Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

A new biomarker for the aging brain

Researchers at the RIKEN Center for Biosystems Dynamics Research (BDR) in Japan have identified changes in the aging brain related to blood circulation. Published in the scientific journal Brain, the study found that natural age-related enlargement of the ventricles—a condition called ventriculomegaly—was associated with a lag in blood drainage from a specific deep region of the brain. The lag can be detected easily with MRI, making it a potential biomarker for predicting ventriculomegaly and the aging brain, which can then be treated quickly.

Ventriculomegaly is an abnormal condition in which fluid accumulates in the ventricles of the without properly draining, making them enlarged. Although ventricular enlargement within normal range is not itself considered a disease, when left unchecked it can lead to ventriculomegaly and dementia resulting from normal pressure hydrocephalus. In their study, the team found that ventriculomegaly was associated with changes in circulation of the brain. “We found an age-related perfusion timing shift in the brain’s venous systems whose lifespan profile was very similar to, but slightly preceded that of ventricular enlargement,” explains first author Toshihiko Aso.

After blood circulates through the brain providing necessary oxygen, the deoxygenated blood must return to the heart though our veins. This happens through two pathways, one draining blood from regions close to the surface of the brain, and the other from areas deep in the brain. By using MRI to measure changes in , the team at BDR recently found that as we age, the time it takes for blood to drain through these two pathways becomes out of sync. The result is a time lag between the deep drainage and the surface pathway, which increases with age.

Eybna and CannaSoul, Top Cannabis R&D Firms, Join Forces to Prove a Proprietary Terpene Formulation for Treating Viral Infections via Modulation of Cytokine Storm

TEL AVIV, Israel, April 22, 2020 /PRNewswire/ — Prof. Dedi (David) Meiri, Chairman and CSO of CannaSoul and Nadav Eyal, Co-founder and CEO of Eybna Technologies Ltd, announced today the companies have jointly engaged in a mutual assays of CannaSoul’s (through its Myplant-Bio subsidiary) Cytokine Storm Assay and Eybna’s Novel NT-VRL™ formulation dedicated for treatment and prevention of viral infections — specifically for high-risk populations and treatment of actively ill patients.